ACADEMY OF MANAGED CARE PHARMACY for ACADEMY OF MANAGED CARE PHARMACY

Medicare/Medicaid MMM

Submitted comments to CMS on the CY 2018 updates to the Quality Payment Program. Submitted comments to CMS on the Draft CY 2018 Medicare Part B Physician Fee Schedule.

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA)

Budget/Appropriations BUD

Letter submitted to the Honorable Kevin Brady as part of the National Quality Forum (NQF) coalition in support of continued funding for the NQF as part of the funding for Medicare. Participated in a lobby days program as a member of the Alliance for a Stronger FDA and met with Senate members of appropriations committee to request adequate funding for the FDA.

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS)

Pharmacy PHA

Letters of support for the CREATES Act (H.R. 2212 and S. 974), (H.R. 3545) The Overdose Prevention and Patient Safety Act and the Pharmaceutical Information Exchange Act(H.R. 2026). Comments to FDA on Hatch-Waxman reform to advocate for prohibition of strategies that unnecessarily delay the entry of generic drugs into the marketplace.

Contacted: Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 3545 (115th), S. 974 (115th), H.R. 2026 (115th), H.R. 2212 (115th)